Chen, S. et al. Nanotechnology-based mRNA vaccines. Nat. Rev. Strategies Primers 3, 63 (2023).
Chaudhary, N., Weissman, D. & Whitehead, Ok. A. mRNA vaccines for infectious illnesses: rules, supply and scientific translation. Nat. Rev. Drug Discov. 20, 817–838 (2021).
Gardin, A., Remih, Ok., Gonzales, E., Andersson, E. R. & Strnad, P. Fashionable therapeutic approaches to liver-related issues. J. Hepatol. 76, 1392–1409 (2022).
Liu, C. et al. mRNA-based most cancers therapeutics. Nat. Rev. Most cancers 23, 526–543 (2023).
Jiang, Y., Li, Y. & Zhu, B. T-cell exhaustion within the tumor microenvironment. Cell Dying Dis. 6, e1792 (2015).
Chow, A., Perica, Ok., Klebanoff, C. A. & Wolchok, J. D. Medical implications of T cell exhaustion for most cancers immunotherapy. Nat. Rev. Clin. Oncol. 19, 775–790 (2022).
Ito, A., Kondo, S., Tada, Ok. & Kitano, S. Medical improvement of immune checkpoint inhibitors. Biomed. Res. Int. 2015, 605478 (2015).
Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25–39 (2020).
Martins, F. et al. Adversarial results of immune-checkpoint inhibitors: epidemiology, administration and surveillance. Nat. Rev. Clin. Oncol. 16, 563–580 (2019).
Buchbinder, E. I. & Hodi, F. S. Immune-checkpoint blockade—sturdy most cancers management. Nat. Rev. Clin. Oncol. 13, 77–78 (2016).
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F. & Opitz, C. A. Tryptophan metabolism as a standard therapeutic goal in most cancers, neurodegeneration and past. Nat. Rev. Drug Discov. 18, 379–401 (2019).
Brochez, L., Chevolet, I. & Kruse, V. The rationale of indoleamine 2,3-dioxygenase inhibition for most cancers remedy. Eur. J. Most cancers 76, 167–182 (2017).
Guo, Y. et al. Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for most cancers immunotherapy. Biomaterials 276, 121018 (2021).
Singer, Ok., Gottfried, E., Kreutz, M. & Mackensen, A. Suppression of T-cell responses by tumor metabolites. Most cancers Immunol. Immunother. 60, 425–431 (2011).
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E. & Prendergast, G. C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory goal of the most cancers suppression gene Bin1, potentiates most cancers chemotherapy. Nat. Med. 11, 312–319 (2005).
Phan, T. et al. Salmonella-mediated remedy focusing on indoleamine 2, 3-dioxygenase 1 (IDO) prompts innate immunity and mitigates colorectal most cancers development. Most cancers Gene Ther. 27, 235–245 (2020).
Moreno, A. C. R. et al. The mixed use of melatonin and an indoleamine 2,3-dioxygenase-1 inhibitor enhances vaccine-induced protecting mobile immunity to HPV16-associated tumors. Entrance. Immunol. 9, 1914 (2018).
Spranger, S. et al. Up-regulation of PD-L1, IDO, and Tregs within the melanoma tumor microenvironment is pushed by CD8+ T cells. Sci. Transl. Med. 5, 200ra116–200ra116 (2013).
Alahdal, M., Xing, Y., Tang, T. & Liang, J. 1-Methyl-D-tryptophan reduces tumor CD133+ cells, Wnt/β-catenin and NF-κβp65 whereas enhances lymphocytes NF-κβ2, STAT3, and STAT4 pathways in murine pancreatic adenocarcinoma. Sci. Rep. 8, 9869 (2018).
Shang, Ok. et al. Gene silencing of indoleamine 2,3-dioxygenase 1 inhibits lung most cancers development by suppressing T-cell exhaustion. Oncol. Lett. 19, 3827–3838 (2020).
Wu, D. & Zhu, Y. Position of kynurenine in selling the era of exhausted CD8+ T cells in colorectal most cancers. Am. J. Transl. Res. 13, 1535–1547 (2021).
Yousef, Z. et al. Part II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the therapy of sufferers with superior melanoma. J. Immunother. Most cancers 9, e002057 (2021).
Kwiatkowska, I. et al. Evaluation of an anticancer impact of the simultaneous administration of MM-129 and indoximod within the colorectal most cancers mannequin. Cancers 16, 122 (2024).
Johnson, T. S. et al. Indoximod-based chemo-immunotherapy for pediatric mind tumors: a first-in-children section I trial. Neuro-Oncol. 26, 348–361 (2023).
Briukhovetska, D. et al. Interleukins in most cancers: from biology to remedy. Nat. Rev. Most cancers 21, 481–499 (2021).
Starbeck-Miller, G. R., Xue, H.-H. & Harty, J. T. IL-12 and kind I interferon delay the division of activated CD8 T cells by sustaining high-affinity IL-2 signaling in vivo. J. Exp. Med. 211, 105–120 (2013).
Cirella, A. et al. Intratumoral gene switch of mRNAs encoding IL12 together with decoy-resistant IL18 improves native and systemic antitumor immunity. Most cancers Immunol. Res. 11, 184–198 (2023).
Wang, P. et al. Re-designing interleukin-12 to boost its security and potential as an anti-tumor immunotherapeutic agent. Nat. Commun. 8, 1395 (2017).
Nguyen, Ok. G. et al. Localized interleukin-12 for most cancers immunotherapy. Entrance. Immunol. 11, 575597 (2020).
Agarwal, Y. et al. Intratumourally injected alum-tethered cytokines elicit potent and safer native and systemic anticancer immunity. Nat. Biomed. Eng. 6, 129–143 (2022).
Jorgovanovic, D., Music, M., Wang, L. & Zhang, Y. Roles of IFN-γ in tumor development and regression: a evaluate. Biomark. Res. 8, 49 (2020).
Hotz, C. et al. Native supply of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication throughout a number of preclinical tumor fashions. Sci. Transl. Med. 13, eabc7804 (2021).
Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA supply. Nat. Rev. Mater. 6, 1078–1094 (2021).
Wang, C., Zhang, Y. & Dong, Y. Lipid nanoparticle–mRNA formulations for therapeutic purposes. Acc. Chem. Res. 54, 4283–4293 (2021).
Couvreur, P., Lepetre-Mouelhi, S., Garbayo, E. & Blanco-Prieto, M. J. Self-assembled lipid–prodrug nanoparticles. Nat. Rev. Bioeng. 1, 749–768 (2023).
Ding, C., Chen, C., Zeng, X., Chen, H. & Zhao, Y. Rising methods in stimuli-responsive prodrug nanosystems for most cancers remedy. ACS Nano 16, 13513–13553 (2022).
Delahousse, J., Skarbek, C. & Paci, A. Prodrugs as drug supply system in oncology. Most cancers Chemother. Pharmacol. 84, 937–958 (2019).
Yang, B., Gao, J., Pei, Q., Xu, H. & Yu, H. Engineering prodrug nanomedicine for most cancers immunotherapy. Adv. Sci. 7, 2002365 (2020).
Kyu Shim, M., Yang, S., Solar, I.-C. & Kim, Ok. Tumor-activated carrier-free prodrug nanoparticles for focused most cancers immunotherapy: preclinical proof for protected and efficient drug supply. Adv. Drug Deliv. Rev. 183, 114177 (2022).
Zhou, L. et al. Engineering polymeric prodrug nanoplatform for vaccination immunotherapy of most cancers. Nano Lett. 20, 4393–4402 (2020).
Shi, L., Lin, S., Zhou, F., Jiang, H. & Zhang, J. Current advances in engineering prodrug-based nanomedicines for most cancers remedy. Mater. Adv. 5, 4634–4659 (2024).
Tan, J. et al. Coordinating exterior and built-in triggers for tunable degradation of polymeric nanoparticles by way of cycle amplification. J. Am. Chem. Soc. 143, 13738–13748 (2021).
Mukalel, A. J. et al. Oxidized mRNA lipid nanoparticles for in situ chimeric antigen receptor monocyte engineering. Adv. Funct. Mater. 34, 2312038 (2024).
Ding, Y., Dai, Y., Wu, M. & Li, L. Glutathione-mediated nanomedicines for most cancers analysis and remedy. Chem. Eng. J. 426, 128880 (2021).
Wang, Q., Guan, J., Wan, J. & Li, Z. Disulfide primarily based prodrugs for most cancers remedy. RSC Adv. 10, 24397–24409 (2020).
Riley, J. L. PD-1 signaling in main T cells. Immunol. Rev. 229, 114–125 (2009).
Del Vecchio, M. et al. Interleukin-12: organic properties and scientific utility. Clin. Most cancers Res. 13, 4677–4685 (2007).
Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133–146 (2003).
Okamura, H. et al. Cloning of a brand new cytokine that induces IFN-γ manufacturing by T cells. Nature 378, 88–91 (1995).
Zhang, H. & Barz, M. Investigating the soundness of RNA-lipid nanoparticles in organic fluids: unveiling its essential position for understanding LNP efficiency. J. Management. Launch 381, 113559 (2025).
Shelef, O., Gnaim, S. & Shabat, D. Self-immolative polymers: an rising class of degradable supplies with distinct disassembly profiles. J. Am. Chem. Soc. 143, 21177–21188 (2021).
Jain, R. et al. MicroRNAs allow mRNA therapeutics to selectively program most cancers cells to self-destruct. Nucleic Acid Ther. 28, 285–296 (2018).
Hiam-Galvez, Ok. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in most cancers. Nat. Rev. Most cancers 21, 345–359 (2021).
Tang, L., Huang, Z., Mei, H. & Hu, Y. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Sign Transduct. Goal. Ther. 8, 306 (2023).
Brito-Orama, S. & Sheth, R. A. The modern panorama and future instructions of intratumoral immunotherapy. J. Immunother. Summary. Oncol. 6, 84–90 (2023).
De Lombaerde, E., De Wever, O. & De Geest, B. G. Supply routes matter: security and efficacy of intratumoral immunotherapy. Biochim. Biophys. Acta Rev. Most cancers 1875, 188526 (2021).
Melero, I., Castanon, E., Alvarez, M., Champiat, S. & Marabelle, A. Intratumoural administration and tumour tissue focusing on of most cancers immunotherapies. Nat. Rev. Clin. Oncol. 18, 558–576 (2021).
Gong, N. et al. Enhancing in situ most cancers vaccines utilizing supply applied sciences. Nat. Rev. Drug Discov. 23, 607–625 (2024).